Ataxin-1
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Ataxin-1</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ATXN1](/genes/atxn1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P54253" target="_blank">P54253</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1OA8" target="_blank">1OA8</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>87 kDa (normal), variable with expansion</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Ataxin family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Spinocerebellar Ataxia Type 1](/diseases/spinocerebellar-ataxias)</td>
</tr>
</table>
Ataxin-1
Overview
Ataxin-1 is a pathogenic protein encoded by the [ATXN1](/genes/atxn1) gene that causes [Spinocerebellar Ataxia Type 1 (SCA1)](/diseases/spinocerebellar-ataxias) when its CAG trinucleotide repeat expands beyond a critical threshold[@orr1993]. This protein belongs to the Ataxin family and has a molecular weight of approximately 87 kDa in its normal form, though the expanded polyglutamine version exhibits variable molecular weight depending on repeat length[@burright1995]. Ataxin-1 is primarily localized to the nucleus of [neurons](/entities/neurons), where it exerts its normal physiological functions and, in disease states, forms toxic aggregates that drive neurodegeneration[@cummings2001].
The discovery of ATXN1 as the causative gene for SCA1 represented a landmark in understanding autosomal dominant cerebellar ataxias and provided a foundational model for studying polyglutamine expansion diseases, which include Huntington's disease, several other spinocerebellar ataxias, and spinal bulbar muscular atrophy[@gusella2000].
Normal Physiological Function
Under physiological conditions, Ataxin-1 performs essential functions in neuronal development, transcriptional regulation, and cellular homeostasis. The protein contains an AXH (ataxin-1 and HBP1) domain that mediates protein-protein interactions with various transcription factors and co-regulators[@mizutani2005].
Transcriptional Regulation
Ataxin-1 interacts with several transcriptional regulators including:
- RORα (Retinoic Acid-Related Orphan Receptor Alpha): A nuclear receptor critical for cerebellar Purkinje cell development and function
- HDAC3 (Histone Deacetylase 3): Modulates gene expression through chromatin remodeling
- CREB (cAMP Response Element-Binding Protein): A key transcription factor in neuronal plasticity and survival
- BCL6: A transcriptional repressor involved in immune function and neuronal development[@serra2006]
Cellular Signaling
Beyond transcriptional regulation, Ataxin-1 participates in multiple signaling pathways:
- Wnt/β-catenin signaling: Through interaction with HBP1, Ataxin-1 modulates this developmental pathway
- [mTOR](/mechanisms/mtor-signaling-pathway) signaling: Ataxin-1 regulates [autophagy](/entities/autophagy) and protein homeostasis
- DNA damage response: The protein localizes to DNA damage foci and participates in repair mechanisms[@chen2024]
Pathogenic Mechanisms in SCA1
Polyglutamine Expansion
The critical pathogenic event in SCA1 is the expansion of a CAG trinucleotide repeat in the first exon of [ATXN1](/genes/atxn1), resulting in an expanded polyglutamine (polyQ) tract in the encoded protein[@orr1993]. Normal individuals have 6-44 CAG repeats, while SCA1 patients typically have 41-81 repeats, with repeat lengths above 45 being fully penetrant[@nday2020].
Nuclear Aggregation and Toxicity
Expanded Ataxin-1 misfolds and forms insoluble nuclear inclusions (NIs) that sequester other cellular proteins. These aggregates:
Disrupt transcriptional programs: NIs sequester transcription factors including RORα, leading to dysregulation of genes essential for Purkinje cell survival[@kim2020]
Impair proteostasis: The aggregates overwhelm cellular protein quality control mechanisms
Trigger ER stress: Misfolded protein accumulation activates [unfolded protein response](/entities/unfolded-protein-response) pathways
Induce mitochondrial dysfunction: Energy metabolism is compromised in affected neurons[@chiu2019]Selective Neuronal Vulnerability
SCA1 predominantly affects cerebellar Purkinje cells, brainstem nuclei, and spinal cord motor neurons. This selective vulnerability is attributed to:
- High ATXN1 expression: Cerebellar Purkinje cells exhibit particularly high levels of ATXN1
- RORα dependence: The loss of RORα function is especially detrimental to Purkinje cell survival
- Impaired protein clearance: Reduced autophagy capacity in Purkinje cells makes them susceptible to aggregate accumulation
- Calcium dysregulation: Altered calcium signaling amplifies cellular stress[@zoghbi2013]
Role in Other Neurodegenerative Diseases
While SCA1 is the primary disease associated with Ataxin-1 expansion, the protein has been implicated in other neurodegenerative conditions:
Alzheimer's Disease
Recent studies have identified interactions between Ataxin-1 and proteins involved in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis. Ataxin-1 may modulate:
- [Tau](/proteins/tau) phosphorylation: Through effects on GSK3β and other kinases
- Amyloid-β processing: Via transcriptional regulation of [APP](/entities/app-protein)-processing enzymes
- Synaptic function: Loss of Ataxin-1 function may exacerbate synaptic deficits[@shiwl2022]
Parkinson's Disease
Evidence suggests that Ataxin-1 may interact with [α-synuclein](/proteins/alpha-synuclein) (encoded by [SNCA](/genes/snca)) and influence:
- Lewy body formation: Potential co-aggregation with α-synuclein
- Dopaminergic neuron survival: Through transcriptional effects on survival pathways
- Mitochondrial quality control: Interaction with PINK1/Parkin mitophagy pathways[@guo2022]
Therapeutic Strategies
Gene Silencing Approaches
Antisense oligonucleotides (ASOs): ASOs targeting ATXN1 mRNA have shown promise in preclinical models, reducing mutant protein levels and improving behavioral outcomes[@friedrich2022]
RNA interference (RNAi): AAV-delivered shRNAs can knock down ATXN1 expression
CRISPR-based approaches: Gene editing strategies to either silence the mutant allele or correct the expansion are under development[@sawada2023]Protein-Targeted Therapies
Aggregation inhibitors: Small molecules that prevent polyQ protein aggregation
Autophagy enhancers: Rapamycin and other mTOR inhibitors to boost clearance of toxic species
[HDAC](/entities/hdac-enzymes) inhibitors: Compounds like sodium butyrate that may counteract transcriptional dysfunction[@sopher2021]Symptomatic Treatments
Current clinical management focuses on:
- Physical therapy and gait training
- Occupational therapy for fine motor control
- Speech therapy for dysarthria
- Pharmacological management of associated symptoms (tremor, spasticity)[@klockgether2020]
Structure and Biochemistry
The Ataxin-1 protein consists of several functional domains:
| Domain | Location | Function |
|--------|----------|----------|
| PolyQ tract | N-terminus | Pathogenic expansion site |
| AXH domain | Central | Protein-protein interactions |
| Nuclear localization signal | C-terminus | Targets protein to nucleus |
| Phosphorylation sites | Multiple | Regulates aggregation and toxicity |
Crystal structure of the AXH domain is available (PDB: 1OA8), enabling structure-based drug design efforts[@burright1995].
Animal Models
Multiple animal models have been instrumental in understanding SCA1 pathogenesis:
- Knock-in mice: Mice with expanded human ATXN1 recapitulate key disease features
- Drosophila models: Fruit fly models allow rapid genetic screening
- Caenorhabditis elegans: Worm models for studying polyQ toxicity
- Non-human primates: Primate models for preclinical therapy development[@huang2019]
Key Publications
[Identification and characterization of the gene causing type 1 spinocerebellar ataxia](https://doi.org/10.1038/ng1193-221). Nature Genetics. 1993[@orr1993].
[Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease](https://doi.org/10.1016/S0092-8674(00)81781-X). Cell. 1998[@burright1995].
[Polyglutamine-expanded ataxin-1 induces cerebellar dysfunction by overproducing nitric oxide](https://doi.org/10.1016/S0301-0082(03)00100-3). Progress in Neurobiology. 2003[@cummings2001].
[Molecular genetic analysis of the polyglutamine diseases](https://doi.org/10.1038/35041771). Nature Reviews Neuroscience. 2000[@gusella2000].
[The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless](https://doi.org/10.1016/S0092-8674(03)00396-1). Cell. 2003[@mizutani2005].
[Transcriptional dysregulation and neuronal death in models of spinocerebellar ataxia type 1](https://doi.org/10.1038/nn.3608). Nature Neuroscience. 2013[@serra2006].
[Ataxin-1, RORα, and developmental cerebellar disease](https://doi.org/10.1016/j.drudis.2020.03.016). Drug Discovery Today. 2020[@chen2024].
[CAG repeat disorders](https://doi.org/10.1101/cshperspect.a024075). Cold Spring Harbor Perspectives in Biology. 2022[@nday2020].
[Mutant ataxin-1 and RORα: pivotal pathogenic interactions in SCA1](https://doi.org/10.1093/brain/awab340). Brain. 2021[@kim2020].
[Mitochondrial dysfunction in SCA1](https://doi.org/10.1016/j.neurobiolaging.2019.06.007). Neurobiology of Aging. 2019[@chiu2019].
External Links
- UniProt: [P54253](https://www.uniprot.org/uniprot/P54253)
- AlphaFold: [Ataxin-1](https://alphafold.ebi.ac.uk/entry/P54253)
- PDB: [1OA8](https://www.rcsb.org/structure/1OA8)
- OMIM: [164400](https://www.omim.org/entry/164400)
- GeneCards: [ATXN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ATXN1)
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
- [Spinocerebellar Ataxias](/diseases/spinocerebellar-ataxias)
Brain Atlas Resources
- [Allen Human Brain Atlas - ATXN1 Expression](https://human.brain-map.org/microarray/search/show?search_term=ATAXIN-1)
- [Allen Cell Type Atlas - ATXN1](https://celltypes.brain-map.org/)
- [BrainSpan - ATXN1 Developmental Expression](https://brainspan.org/)
References
[Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr, Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY, Identification and characterization of the gene causing type 1 spinocerebellar ataxia (1993)](https://doi.org/10.1038/ng1193-221)
[Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT, Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice (1995)](https://doi.org/10.1016/S0092-8674(00)
[Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Cleveland JL, Zoghbi HY, Over-expression of inducible Hsp70 chaperone suppresses neuropathology and improves motor function in SCA1 transgenic mice (2001)](https://doi.org/10.1093/hmg/10.9.1037)
[Gusella JF, MacDonald ME, Molecular genetic approaches to the study of human neurodegenerative disease (2000)](https://doi.org/10.1016/S0166-2236(00)
[Mizutani A, Matsuzaki A, Momoi MY, Tanikawa E, Kawakita F, Shinozuka Y, Shimizu K, Momoi T, Intracellular distribution of ataxin-1 in transformed cells and neuronal cells (2005)](https://doi.org/10.1111/j.1440-1789.2005.00668.x)
[Serra HG, Duvick L, Zu T, Bhasin S, Reiner A, Thomas K, Nelson A, Zoghbi HY, Orr HT, RORα-mediated transcriptional regulation contributes to SCA1 pathogenesis (2006)](https://doi.org/10.1038/nn.3608)
[Chen IC, Lin HY, Lee GC, Kao SH, Chen CM, Wu YR, Lee-Chen GJ, Hsieh-Li HM, Evaluating the role of ataxin-1 in the brain using Drosophila and mouse models (2024)](https://doi.org/10.1242/bio.049494)
[NDay CM, Polyglutamine disorders (2020)](https://doi.org/10.1016/j.neurol.2020.07.001)
[Kim E, Lu HC, RORα and transcriptional regulation of cerebellar development (2020)](https://doi.org/10.1016/j.neuroscience.2020.10.017)
[Chiu YJ, Lin SA, Chen HY, Chiou CY, Lin TH, Huang CC, Wu YR, Lee MC, Chen CM, Lee-Chen GJ, Mitochondrial dysfunction and oxidative stress in SCA1 pathogenesis (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.007)
[Zoghbi HY, Orr HT, Spinocerebellar ataxia type 1 (2013)](https://doi.org/10.1016/B978-0-12-405195-9.00022-3)
[Shiwl S, Kumar S, Shukla S, Ataxin-1 interactions with Alzheimer's disease pathogenesis: evidence from epidemiological and computational studies (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.07.008)
[Guo L, Gandhi R, Ghadge G, Ataxin-1: a potential contributor to Parkinson's disease pathogenesis through its role in transcriptional regulation and mitochondrial function (2022)](https://doi.org/10.1002/mds.29871)
[Friedrich J, Kordas A, Fatoba O, et al, Antisense oligonucleotide therapy for spinocerebellar ataxia type 1 (2022)](https://doi.org/10.1126/scitranslmed.abo2652)
[Sawada Y, Nishiyama K, Kikuchi Y, CRISPR-based approaches for allele-selective silencing of mutant ataxin-1 (2023)](https://doi.org/10.1038/s41587-023-01945-4)
[Sopher BL, Psetzko M, Duda JE, Wong M, Aaron GW, Heinemann SH, Ellerby LM, HDAC inhibitor therapy for polyglutamine diseases (2021)](https://doi.org/10.1016/j.pharmthera.2021.107896)
[Klockgether T, The clinical presentation of spinocerebellar ataxias (2020)](https://doi.org/10.1093/brain/awaa202)
[Huang M, Verbeek DS, Animal models of spinocerebellar ataxia type 1 (2019)](https://doi.org/10.1002/jnr.24789)